

Detection of SARS-CoV-2-specific Antibodies via Rapid Diagnostic Immunoassays in COVID-19 Patients with Positive SARS-CoV-2 RNA Real-time Reverse Transcriptase PCR Results

Jira Chansaenroj

Center of Excellence in Clinical virology, Chulalongkorn University

Ritthideach Yorsaeng

Center of Excellence in Clinical Virology, Chulalongkorn University

Nawarat Posuwan

Center of Excellence in Clinical Virology, Chulalongkorn University

Jiratchaya Puenpa

Center of Excellence in Clinical Virology, Chulalongkorn University

Natthinee Sudhinaraset

Center of Excellence in Clinical Virology, Chulalongkorn University

Chintana Chirathaworn

Center of Excellence in Clinical Virology, Chulalongkorn University

Yong Poovorawan (✉ Yong.P@chula.ac.th)

Chulalongkorn University

Research

Keywords: antibody, COVID-19, immunoassay, rapid diagnostic test, SARS-CoV-2

Posted Date: December 11th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-125190/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published on March 9th, 2021. See the published version at <https://doi.org/10.1186/s12985-021-01530-2>.

Abstract

Background: Efficient monitoring and control of coronavirus disease 2019 (COVID-19) requires access to diagnostic tests, and serological diagnostic testing is desirable. In the current study antibodies were investigated in patients recently diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Methods: Cross-sectional data derived from 245 patients in whom SARS-CoV-2 infection had been confirmed via real-time reverse transcriptase-polymerase chain reaction were obtained. Samples were acquired at the onset of COVID-19 symptoms or the first detection of SARS-CoV-2 in asymptomatic patients, and at another timepoint within 8 weeks thereafter. All specimens were tested simultaneously using an IgM/IgG rapid diagnostic test (RDT), nucleocapsid-based and spike protein-based IgG immunoassays, and a spike protein-based IgA immunoassay. Blood donor samples obtained in 2018 were used as negative controls, and to assess cross-reactivity with seasonal coronaviruses.

Results: The IgM/IgG RDT exhibited 97.5% sensitivity and 97.2% specificity compared with a nucleocapsid-IgG-based chemiluminescent microparticle immunoassay, and 98.4% sensitivity and 93.6% specificity compared with a spike protein-based ELISA. IgG RDT detection was 100% concordant with IgG and IgA immunoassays ($P < 0.001$). IgM, IgG, and IgA were low during the first week after COVID-19 symptom onset or the detection of SARS-CoV-2 RNA. IgM began decreasing after 4 weeks, whereas IgG and IgA remained at appreciable levels over the 8-week study period. No cross-reactivity with seasonal coronaviruses was detected.

Conclusions: IgM/IgG RDTs alone or combined with molecular diagnostic tests may be useful for identifying recent SARS-CoV-2 infection.

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes an acute respiratory tract illness known as coronavirus disease 2019 (COVID-19) [1]. The incubation period ranges from 1 to 14 days. SARS-CoV-2 can be initially detected in upper respiratory tract samples 1 to 2 days before symptom onset, and can persist for 7 to 12 days in moderate cases and for up to 2 weeks in severe cases [2]. Due to a rapid rise in the number of cases and uncontrolled spread, the World Health Organization declared SARS-CoV-2 a world pandemic on 11 March 2020 [3]. Awareness of COVID-19 outbreaks in individual countries is important with regard to effective diagnosis and control. Many countries can control morbidity, and asymptomatic SARS-CoV-2 infection does occur.

The most important strategies for controlling transmission are active case identification, patient isolation, contact tracing, and social distancing [4]. Accordingly, the use of rapid and easy to perform diagnostic methods during the early phase of COVID-19 has facilitated early laboratory diagnosis of infection with high sensitivity, particularly in asymptomatic and/or preclinical patients, and they are evidently a key factor to success [5]. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-based methods designed to detect SARS-CoV-2 in nasopharyngeal swabs are currently the gold standard for COVID-19 diagnosis [6]. Notably however, molecular diagnostic approaches require technical expertise and equipment, and can be comparatively costly.

Serological assessments are an alternative for surveillance purposes, and include point-of-care techniques that may constitute readily available and easy to apply tools [7]. They can generally be performed in relatively small community settings, facilitating broad application. Their utility may be limited by the fact that antibodies appear later during the disease course. Positive molecular testing is reportedly crucial for optimal serological testing sensitivity, with the best results evidently being achieved at least 14 days after a positive real-time RT-PCR result. At later post-infection stages, serology can become negative [8,9]. Patients with more severe symptoms develop greater immune responses against viral proteins than asymptomatic patients [10, 11].

Immunoassays are the standard diagnostic method for precise and quantitative detection, wherein binding of specific antibodies is used to determine whether a patient has previously been infected [12]. The sensitivity of antibody testing evidently depends on sampling time, but in most studies the median time to antiviral IgG seroconversion is reportedly between 6 and 14 days from symptom onset, and high IgG persists for at least 7 weeks [11]. Several assays are currently available for the detection of antibodies against various SARS-CoV-2 proteins, including the spike protein, nucleocapsid protein, and receptor binding domain. Variable clinical sensitivity and specificity of these tests has been reported in numerous independent studies [11, 13, 14]. Lateral flow immunoassays are an attractive alternative, as they require less operator skill and can potentially be utilized in point-of-care settings.

In the current study serological assays for COVID-19 diagnosis including the COVID-19 IgM/IgG rapid diagnostic test (RDT) were assessed using serum samples from patients with real-time RT-PCR-confirmed SARS-CoV-2 infection, and the results were compared with those derived from semi-quantitative IgG assays. Serum samples collected from volunteers in 2018, *i.e.*, before the COVID-19 outbreak, were used to test specificity.

Materials And Methods

The study protocol was approved by the Research Ethics Committee of the Faculty of Medicine, Chulalongkorn University (IRB number 572/63), and that committee waived the requirement for consent because the samples used were obtained during the course of routine preventive measures and were de-identified and anonymous.

Specimen collection

A cross-sectional set of serum samples derived from 245 patients in whom SARS-CoV-2 infection had been confirmed via real-time RT-PCR of nasal swab specimens or who had a previous SARS-CoV-2-positive diagnostic test result in their medical record from the hospital and public health center were used in the study. Samples from all 245 patients (138 from the National Blood Center, 107 from Bangkok Metropolitan Administration Hospital) were obtained during the period between COVID-19 symptom onset and serum sample acquisition for serology testing to monitor the presence of antibodies against SARS-CoV-2. For samples from asymptomatic patients, the period was calculated from the first date of SARS-CoV-2 detection via real-time RT-PCR to the date of serum sample acquisition. The time enrolling in this study ranged from 2 days to 60 days. A total of 130 blood donor specimens collected in 2018 were used as negative control samples.

IgM/IgG rapid diagnostic test

The Standard Q COVID-19 IgM/IgG Combo test (SD biosensor, Chungcheongbuk-do, Republic of Korea) is a rapid chromatographic immunoassay for the qualitative detection of SARS-CoV-2-specific antibodies. The test utilizes recombinant COVID-19 nucleocapsid protein conjugated to colloidal gold particles as detectors, and SARS-CoV-2-specific IgM and IgG antibodies are detected simultaneously. A violet test line is visible if SARS-CoV-2 antibodies are present in the specimen. The visual intensity of the violet test line varies depending on the amount of SARS-CoV-2 antibodies present in the specimen. A visual intensity ratio ranging from 0 to 3 compared to a control line is scored, where 0 = no intensity, 1 = weak intensity, 2 = medium intensity, and 3 = strong intensity. In the current study all results of this assay were interpreted by three different people independently, to measure positivity.

Spike protein IgG and IgA ELISAs

Anti-SARS-CoV-2 IgG and IgA ELISAs (EUROIMMUN, Lubeck, Germany) are enzymatic immunoassays that provide semi-quantitative *in vitro* determination of human IgG and IgA antibodies against the S1 domain of the SARS-CoV-2 spike protein. Optical density was measured at 450 nm. The results can be evaluated semi-quantitatively by calculating the ratio of the control or patient sample over the extinction of the calibrator. Samples with a cutoff ratio higher than 1.1 were considered positive. All ELISAs were tested and interpreted automatically using the EUROIMMUN Analyzer I-2P machine (Lubeck, Germany).

IgG nucleoprotein chemiluminescent microparticle immunoassay

The SARS-CoV-2 IgG chemiluminescent microparticle immunoassay (CMIA) (Abbott Ireland Diagnostics Division, Sligo, Ireland) is an automated two-step immunoassay for the quantitative detection of IgG antibodies against SARS-CoV-2. Samples were analyzed using an Abbott ARCHITECT I 1000SR instrument. The ARCHITECT I system calculates the mean calibrator chemiluminescent signal. Results derived from test samples are measured as relative light units (RLU) and determined via comparison with the calibrator, and the cutoff is 1.4. There is a direct relationship between the amount of SARS-CoV-2 antibodies in the sample and the RLU detected by the system.

Statistical analysis

Sensitivity and specificity for detection of the presence of SARS-CoV-2 IgG antibodies were evaluated. Statistical analyses were performed using IBM SPSS statistics for Windows, version 21 (IBM Corp., Armonk, NY, USA). Agreement rates and kappa coefficients between immunoassays and RDTs were analyzed. The association between the amount of SARS-CoV-2 antibodies and the time period after COVID-19 symptom onset was analyzed using the Chi-square test. Correlations between IgG RDT visual intensity scores and IgG immunoassay relative ratios were analyzed using one-way ANOVA. $P < 0.05$ was considered statistically significant.

Results

In the current study the mean period of time between symptom onset or initial SARS-CoV-2 detection and serum sample acquisition for serology testing was assessed at weeks 1–8. The mean and median period of time in this study were 41.6 ± 17.1 days, 47 days, respectively. Overall, 167/245 (68.2%) individuals tested seropositive for RDT IgM, 198/245 (80.8%) for RDT IgG, 198/245 (80.8%) for CMIA IgG, 189/245 (77.1%) for ELISA IgG, and 196/245 (80.0%) for ELISA IgA. Six patients were RDT IgM-positive but RDT IgG-negative. The RDT positive detection rate increased to 83.3% when both IgG and IgM were assessed (Table 1).

Table 1

Distribution of positivity levels determined via the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and IgG rapid diagnostic test, IgG chemiluminescent microparticle immunoassay, IgG ELISA, and IgA ELISA in patients with SARS-CoV-2 infection.

% Positives																
Asymptomatic								Symptomatic								
Week	Total	RDT			CMIA		ELISA		Total	RTD			CMIA		ELISA	
		IgM	IgG	IgM/IgG	IgG	IgG	IgA		IgM	IgG	IgM/IgG	IgG	IgG	IgG	IgA	
1	8	50.0	75.0	75.0	75.0	75.0	75.0	8	25.0	12.5	25.0	12.5	0.0	0.0		
2	10	50.0	60.0	60.0	80.0	30.0	90.0	7	57.1	42.9	71.4	57.1	28.6	57.1		
3	4	75.0	100.0	100.0	100.0	100.0	100.0	8	100.0	100.0	100.0	100.0	75.0	100.0		
4	0	0.0	0.0	0.0	0.0	0.0	0.0	3	100.0	100.0	100.0	100.0	100.0	100.0		
5	0	0.0	0.0	0.0	0.0	0.0	0.0	13	84.6	84.6	84.6	92.3	76.9	76.9		
6	0	0.0	0.0	0.0	0.0	0.0	0.0	33	66.7	84.8	84.8	81.8	75.6	75.6		
7	0	0.0	0.0	0.0	0.0	0.0	0.0	46	76.1	89.1	89.1	87.0	89.1	87.0		
8	0	0.0	0.0	0.0	0.0	0.0	0.0	105	66.7	82.3	85.7	81.0	84.8	81.9		
Total	22	54.5	72.7	72.7	81.8	59.1	86.4	223	69.5	81.6	84.3	80.7	78.9	79.4		
<p>“Asymptomatic” refers to patients had no symptoms before or after returning a positive realtime reverse transcriptase PCR test. “Symptomatic” refers to patients who had one or more symptoms related to COVID-19 such as fever, cough, sore throat, or difficulty breathing.</p>																
RDT = Rapid diagnosis test (nucleoprotein)																
CMIA = Chemiluminescent microparticle immunoassay (nucleoprotein)																
ELISA = Enzyme-linked immunosorbent assay (spike protein)																

Percentages of seropositive patients and the periods after COVID-19 symptom onset or SARS-CoV-2 detection are shown in Fig. 1. The pattern of RDT IgG seropositivity was similar to that of CMIA IgG, and higher than that of ELISA IgG. RDT IgG exhibited 97.5% sensitivity (95% confidence interval (CI) 94.2–99.2%) and 97.2% specificity (95% CI 93.5–99.1%), and CMIA IgG exhibited 98.4% sensitivity (95% CI 95.4–99.7%) and 93.6% specificity (95% CI 89.0–96.6%) compared to ELISA IgG. Percentages of IgM, IgG, and IgA seropositivity all increased from week 1 after COVID-19 symptom onset or SARS-CoV-2 detection. By week 4, 100% of the patients were seropositive for all three isotypes. Thereafter IgM decreased relatively steadily, whereas IgG and IgA decreased slightly then remained relatively stable.

There was very strong concordance between RDT IgG and the two immunoassays, with Cohen’s kappa coefficients of 0.9 ($P < 0.001$) for CMIA IgG and 0.8 ($P < 0.001$) for ELISA IgG. There was a highly significant positive correlation between visual scores derived from the IgG RDT and IgG positivity levels determined via immunoassays (Fig. 2A–2C). Visual scores and IgG titers in severe patients were significantly higher than they were in mild and asymptomatic patients ($P < 0.001$).

To test specificity, all assays were performed using 130 serum samples from blood donors collected in 2018. All test results were negative.

Discussion

It remains crucial to profile the real population during the COVID-19 epidemic. With regard to disease prognosis and epidemic control, early detection, diagnosis, and isolation are highly advantageous. Although there remains considerable uncertainty regarding the duration of immunity to SAS-CoV-2, the intense knowledge focus on this infection will potentially useful answers in a practicable timeframe of “immunity passport” [15]. Serological assays are important tools for understanding the extent of COVID-19 in the community and identifying individuals who are potentially immune [16]. Serology testing is incorporated into the current local guideline for testing asymptomatic positive cases, and viral clearance is indicated by negative RT-PCR accompanied by specific IgG detection [17, 18].

Incorporating serology assays into diagnostic algorithms and discharge criteria may ease the clinical burden or divert the workload in some situations [19].

In the current study all assays performed using 130 blood donor specimens from volunteers collected in 2018 yielded negative results. Thus, no cross-reactivity with other viruses was detected. In the present study the COVID-19 IgG RDT exhibited sensitivity and specificity > 90%. This compares variably with previous studies, in which wide ranges of sensitivity (30.0–100.0%) and specificity (69.0–100.0%) have been reported. Variation is affected by many things, such as the population sampled and the period of symptom onset [13, 20, 21]. The IgG RDT exhibited very strong concordance with immunoassays, with Cohen's kappa coefficients of 0.9 ($P < 0.001$) for CMIA IgG and 0.8 ($P < 0.001$) for ELISA IgG. Unfortunately, in the current study only IgG immunoassays were compared to the IgG RDT with respect to sensitivity and specificity. However, the results suggest that the RDT can be considered an efficient and useful additional tool for generating population-level epidemiological SARS-CoV-2 infection statistics. The RDT constitutes a viable tool for rapidly identifying subjects who have been exposed to SARS-CoV-2 infection and developed antibodies.

In the current study IgM seropositivity after COVID-19 symptom onset increased from the first week, peaked approximately 3–4 weeks after symptom onset, then decreased moderately. IgG and IgA seropositivity rates peaked approximately 3–4 weeks after symptoms onset, then decreased slightly but remained relatively stable. These results are consistent with SARS-CoV-2 antibody responses reported in several previous studies, in which people who recovered from infection typically had antibodies to the virus 1–2 weeks after infection [17, 22–24]. These antibody dynamics are similar to those of acute viral infections generally, where IgG levels increase as IgM levels start to decrease [17, 25, 26]. In the present study antibody titers and visual IgG scores in severe COVID-19 patients were significantly higher than those in mild and asymptomatic patients. These results are consistent with previous studies, in which antibody levels were associated with COVID-19 severity [10, 27, 28].

The current study had some limitations. It was conducted in a cross-sectional manner, and some clinical data such as viral clearance were not available for all patients. There is also currently no gold standard serological assay for comparative SARS-CoV-2/COVID-19 studies. Lastly, comparable tests to assess the sensitivity and specificity of IgM and IgA were not available during the study.

Conclusion

In conclusion, testing for antibodies may enable the assessment of SARS-CoV-2 infections in asymptomatic and symptomatic patients. The availability of tests with satisfactory performance will result in more accurate determination of the overall spread of COVID-19. The current feasibility assessment of the RDT will guide SARS-CoV-2 antibody testing for the diagnosis and management of the disease. Improved serological testing performance may improve the identification and monitoring of people who have already had contact with SARS-CoV-2. This approach may enable rapid screening of immunity in the population, particularly in areas identified as “hotspots”, which may be informative with regard to future response and preventive measures.

Abbreviations

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19: Coronavirus disease 2019; RT-PCR: Reverse transcriptase-polymerase chain reaction; ELISA: Enzyme-linked immunosorbent assay; CMIA: Chemiluminescent microparticle immunoassay; RDT: Rapid diagnosis test; RLU: Relative light units

Declarations

Ethics approval and consent to participate

The study was conducted with the approval of the Research Ethics Committee of the Faculty of Medicine, Chulalongkorn University (IRB number 572/63), and that committee waived the requirement for consent because the samples used were obtained during the course of routine preventive measures and were de-identified and anonymous.

Consent to participate

not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Funding

This study was supported by a Research Chair Grant from the National Science and Technology Development Agency (P-15-50004), the Center of Excellence in Clinical Virology of Chulalongkorn University/King Chulalongkorn Memorial Hospital (GCE 59-009-30-005), and the Second Century Fund (C2F), Chulalongkorn University to Jira Chansaenroj.

Author contributions

JC drafted the manuscript; JC, RY, NP, and JP analyzed the data and interpreted the results; JC, NS, CC, and YP designed the study; NS, CC, and YP revised the manuscript. All authors reviewed the manuscript, provided critical feedback and approved the final draft.

Acknowledgments

We thank all trainees from the Department of Microbiology and Biochemistry, Faculty of Science, Chulalongkorn University, and all staff from the Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University for their help with the testing.

Conflicts of interest

None declared. There is no involvement from the companies Seegene or SD Biosensor, EUROIMMUN and Abbott Ireland Diagnostics Division.

References

1. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020;5:536-44.
2. Del Rio C and Malani PN. COVID-19-New Insights on a Rapidly Changing Epidemic. *JAMA.* 2020;323:1339-40.
3. WHO. General's opening remarks at the media briefing on COVID-19. <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020>. Accessed on 11 March 2020.
4. Wang Z, Fu Y, Guo Z, Li J, Li J, Cheng H, et al. Transmission and prevention of SARS-CoV-2. *Biochem Soc Trans.* 2020;48:2307-16.
5. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *N Engl J Med.* 2020;382:970-1.
6. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clin Chem Lab Med.* 2020;58:1070-6.
7. Zhen W, Smith E, Manji R, Schron D, Berry GJ. Clinical Evaluation of Three Sample-to-Answer Platforms for Detection of SARS-CoV-2. *J Clin Microbiol.* 2020;58.
8. Andrey DO, Cohen P, Meyer B, Torriani G, Yerly S, Mazza L, et al. Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test. *Eur J Clin Invest.* 2020;50:e13357.
9. Lai CC, Wang CY, Ko WC, Hsueh PR. In vitro diagnostics of coronavirus disease 2019: Technologies and application. *J Microbiol Immunol Infect.* 2020.
10. Choe PG, Kang CK, Suh HJ, Jung J, Kang E, Lee SY, et al. Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients. *Emerg Infect Dis.* 2020;26:2484-7.
11. Naaber P, Hunt K, Pesukova J, Haljasmagi L, Rumm P, Peterson P, et al. Evaluation of SARS-CoV-2 IgG antibody response in PCR positive patients: Comparison of nine tests in relation to clinical data. *PLoS One.* 2020;15:e0237548.
12. Rashed MZ, Kopechek JA, Priddy MC, Hamorsky KT, Palmer KE, Mittal N, et al. Rapid detection of SARS-CoV-2 antibodies using electrochemical impedance-based detector. *Biosens Bioelectron.* 2020;171:112709.
13. Augustine R, Das S, Hasan A, S A, Abdul Salam S, Augustine P, et al. Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World. *J Clin Med.* 2020;9.

14. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ*. 2020;370:m2516.
15. Brown RCH, Kelly D, Wilkinson D, Savulescu J. The scientific and ethical feasibility of immunity passports. *Lancet Infect Dis*. 2020.
16. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA*. 2020;323:2249-51.
17. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis*. 2020;71:778-85.
18. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect*. 2020;9:386-9.
19. Xiao SY, Wu Y, Liu H. Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring. *J Med Virol*. 2020;92:464-7.
20. Ejazi SA, Ghosh S, Ali N. Antibody detection assays for COVID-19 diagnosis: an early overview. *Immunol Cell Biol*. 2020.
21. Guo CC, Mi JQ, Nie H. Seropositivity rate and diagnostic accuracy of serological tests in 2019-nCoV cases: a pooled analysis of individual studies. *Eur Rev Med Pharmacol Sci*. 2020;24:10208-18.
22. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis*. 2020;20:565-74.
23. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020;581:465-9.
24. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis*. 2020.
25. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579:270-3.
26. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med*. 2020;26:845-8.
27. Herroelen PH, Martens GA, De Smet D, Swaerts K, Decavele AS. Humoral Immune Response to SARS-CoV-2. *Am J Clin Pathol*. 2020;154:610-9.
28. GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. *Nat Commun*. 2020;11:3436.

Figures




Figure 1

Distribution of antibody detection in coronavirus disease 2019 (COVID-19) patients classified by week. Qualitative detection was assessed during the period between COVID-19 symptom onset or severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) detection via real-time reverse transcriptase-polymerase chain reaction, and SARS-CoV-2 seropositivity.




Figure 2

Correlations between visual intensity scores and rapid diagnostic test IgG and positivity. Red circles represent patients with severe symptoms (symptomatic patients with pneumonia), green triangles represent patients with mild symptoms (symptomatic patients without pneumonia), and blue squares represent asymptomatic patients. (A) Chemiluminescent microparticle immunoassay IgG. (B) Enzyme-linked immunoassay IgG. (C) Enzyme-linked immunoassay IgA.